A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

Autor: Alice C O'Farrell, Rhys Evans, Johanna M U Silvola, Ian S Miller, Emer Conroy, Suzanne Hector, Maurice Cary, David W Murray, Monika A Jarzabek, Ashwini Maratha, Marina Alamanou, Girish Mallya Udupi, Liam Shiels, Celine Pallaud, Antti Saraste, Heidi Liljenbäck, Matti Jauhiainen, Vesa Oikonen, Axel Ducret, Paul Cutler, Fionnuala M McAuliffe, Jacques A Rousseau, Roger Lecomte, Suzanne Gascon, Zoltan Arany, Bonnie Ky, Thomas Force, Juhani Knuuti, William M Gallagher, Anne Roivainen, Annette T Byrne

Publikováno v: PLoS ONE, Vol 12, Iss 1, p e0169964 (2017)

Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for the early detection of cardiac dysfunction

Externí odkaz: https://doaj.org/article/a50b8f08c3d74280a693b5b4bb9f1718

The Glycosaminoglycan-Binding Domain of PRELP Acts as a Cell Type—Specific NF-κB Inhibitor That Impairs Osteoclastogenesis

Autor: Rucci, Nadia, Rufo, Anna, Alamanou, Marina, Capulli, Mattia, Fattore, Andrea Del, Åhrman, Emma, Capece, Daria, Iansante, Valeria, Zazzeroni, Francesca, Alesse, Edoardo, Heinegård, Dick, Teti, Anna

Publikováno v: The Journal of Cell Biology, 2009 Nov . 187(5), 669-683.

Externí odkaz: https://www.jstor.org/stable/20618368

Artificial Intelligence via Competitive Learning and Image Analysis for Endometrial Malignancies

Autor: George Valasoulis, V Pergialiotis, Nektarios Koufopoulos, Effrosyni Karakitsou, Abraham Pouliakis, Ioannis Panayiotides, Nikolaos Koureas, Niki Margari, Evangelia Alamanou, Vasileia Damaskou

Publikováno v: International Journal of Reliable and Quality E-Healthcare. 8:38-54

Objective of this study is to investigate the potential of an artificial intelligence (AI) technique, based on competitive learning, for the discrimination of benign from malignant endometrial nuclei and lesions. For this purpose, 416 liquid-based cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::924f7848e6368b68b5f92a0aa9ac1af5
https://doi.org/10.4018/ijrqeh.2019100102

Artificial Intelligence for the Identification of Endometrial Malignancies

Autor: Ioannis Panayiotides, Niki Margari, Abraham Pouliakis, Vasileios Sioulas, Vasileia Damaskou, George Chrelias, Emmanouil Terzakis, Effrosyni Karakitsou, Petros Karakitsos, Charalambos Chrelias, Evangelia Alamanou, Asimakis Pappas, Nikolaos Koureas

Publikováno v: International Journal of Reliable and Quality E-Healthcare. 7:37-50

Aim of this article is to investigate the potential of Artificial Intelligence (AI) in the discrimination between benign and malignant endometrial nuclei and lesions. For this purpose, 416 histologically confirmed liquid-based cytological smears were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d32b65e57163964a3ce07cfefee7dc58
https://doi.org/10.4018/ijrqeh.2018040103

Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate

Autor: Rhys Evans, Marina Alamanou, Adam Lafferty, Girish Mallya Udupi, Jochen H. M. Prehn, M. Gehrmann, Alice C. O’Farrell, William M. Gallagher, Ian S. Miller, Mattia Cremona, Naser Monsefi, Henk M.W. Verheul, Maurice Cary, Annette T. Byrne

Publikováno v: PROTEOMICS – Clinical Applications
O'Farrell, A C, Miller, I S, Evans, R, Alamanou, M, Cary, M, Mallya Udupi, G, Lafferty, A, Monsefi, N, Cremona, M, Prehn, J H M, Verheul, H M, Gallagher, W M, Gehrmann, M & Byrne, A T 2019, ' Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate ', Proteomics-Clinical Applications, vol. 13, 1800159 . https://doi.org/10.1002/prca.201800159
Proteomics-Clinical Applications, 13:1800159. Wiley-VCH Verlag
Proteomics Clinical Applications, 13, e1800159
Proteomics Clinical Applications, 13, 4, pp. e1800159

Item does not contain fulltext PURPOSE: The tyrosine kinase inhibitor (TKI) sunitinib is a multi-targeted agent approved across multiple cancer indications. Nevertheless, since approval, data has emerged to describe a worrisome side effect profile in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f57453e7e48ac03141994ac4ce0ebf4c